MiR-101: An Important Regulator of Gene Expression and Tumor EcosystemNing Liu, Deguan Lv, Chunsheng Yang et al.|Cancers|2022Cited by 30
CLDN18.2–targeting antibody–drug conjugate IBI343 in advanced gastric or gastroesophageal junction adenocarcinoma: a phase 1 trialJia Liu, Lin Shen, Meili Sun et al.|Nature Medicine|2025Cited by 29
LBA12 Efficacy and safety of IBI351 (GFH925), a selective KRASG12C inhibitor, monotherapy in patients (pts) with advanced non-small cell lung cancer (NSCLC): Initial results from a registrational phase II studyQing Zhou, Yi‐Long Wu, Xue Meng et al.|Annals of Oncology|2023Cited by 10